开发数字心理健康干预安全性评估流程并获得监管批准:案例研究与学术指南
本文以数字心理健康干预STOP(成功治疗偏执)的随机对照试验为例,详述获得监管批准(MHRA无异议通知)的两大步骤:证明现有安全性并制定风险管理计划,以及制定进一步评估安全性的详细计划。文中呈现了文献综述结果、安全性可行性研究发现、涵盖26种可能危害的风险管理计划、量化概率与严重程度的6点量表、不良事件分类框架及评估15类不良事件的不良事件检查表。
要点
- 获得MHRA无异议通知需完成两大步骤:证明现有安全性并制定风险管理计划,以及制定进一步安全性评估计划。
- STOP试验风险管理计划涵盖26种可能危害,并开发了量化概率与严重程度的6点量表。
- 构建了数字治疗设备不良事件分类框架及评估15类不良事件的不良事件检查表,并用于STOP试验。
核心结论
- 本文分享的案例可作为数字心理健康领域学术与专业人员的指南,提供监管机构对数字心理健康干预临床研究安全性评估要求的见解。
- 文中呈现的方法、量表与工具可轻松适配其他类似研究,期望协助该领域其他研究者为数字心理健康产品寻求监管批准。
研究设计与样本
- 以数字心理健康干预STOP(成功治疗偏执)的随机对照试验作为工作示例,详述获得监管批准(MHRA无异议通知)所需步骤。
主要发现
- 呈现了STOP的文献综述结果、安全性相关可行性研究发现及完整风险管理计划,该计划涵盖26种可能危害。
- 开发了6点量表以量化精神科人群在无治疗师直接支持下接受数字干预时典型风险的概率与严重程度。
- 构建了数字治疗设备不良事件分类框架及评估15类不良事件的不良事件检查表,并用于STOP试验。
关键数值与推荐
- 获得监管批准(MHRA无异议通知)需满足两大目标:第一,证明数字心理健康干预的现有安全性,可参考文献综述、任何可行性/试点安全性数据,并需要风险管理计划;第二,需要制定进一步评估数字心理健康干预安全性的详细计划。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The field of digital mental health has followed an exponential growth trajectory in recent years. While the evidence base has increased significantly, its adoption within health and care services has been slowed by several challenges, including a lack of knowledge from researchers regarding how to navigate the pathway for mandatory regulatory approval. This paper details the steps that a team must take to achieve the required approvals to carry out a research study using a novel digital mental health intervention. We used a randomised controlled trial of a digital mental health intervention called STOP (Successful Treatment of Paranoia) as a worked example. METHODS: The methods section explains the two main objectives that are required to achieve regulatory approval (MHRA Notification of No Objection) and the detailed steps involved within each, as carried out for the STOP trial. First, the existing safety of digital mental health interventions must be demonstrated. This can refer to literature reviews, any feasibility/pilot safety data, and requires a risk management plan. Second, a detailed plan to further evaluate the safety of the digital mental health intervention is needed. As part of this we describe the STOP study's development of a framework for categorising adverse events and based on this framework, a tool to collect adverse event data. RESULTS: We present literature review results, safety-related feasibility study findings and the full risk management plan for STOP, which addressed 26 possible hazards, and included the 6-point scales developed to quantify the probability and severity of typical risks involved when a psychiatric population receives a digital intervention without the direct support of a therapist. We also present an Adverse Event Category Framework for Digital Therapeutic Devices and the Adverse Events Checklist-which assesses 15 different categories of adverse events-that was constructed from this and used in the STOP trial. CONCLUSIONS: The example shared in this paper serves as a guide for academics and professionals working in the field of digital mental health. It provides insights into the safety assessment requirements of regulatory bodies when a clinical investigation of a digital mental health intervention is proposed. Methods, scales and tools that could easily be adapted for use in other similar research are presented, with the expectation that these will assist other researchers in the field seeking regulatory approval for digital mental health products.
引用
- Taher R, Hall CL, Bergin ADG, et al. Developing a process for assessing the safety of a digital mental health intervention and gaining regulatory approval: a case study and academic's guide. Trials. 2024. PMID: 39252100. doi:10.1186/s13063-024-08421-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。